The U.S. Food and Drug Administration has approved NPS Pharmaceuticals Inc.'s drug Natpara to treat a rare hormone disorder, validating a bet by Shire Plc, which recently agreed to acquire NPS for $5.2 billion. Natpara is designed to treat hypoparathyroidism, a condition in which the body's parathyroid gland does not secrete enough parathyroid hormone (PTH). The hormone works with vitamin D to regulate body calcium. Analysts expect the drug to generate peak annual sales of $542 million by 2019, according to Thomson Reuters data. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment